Clinical trials of riluzole in patients with ALS
- 1 October 1996
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 47 (4_suppl_2) , 86S-92S
- https://doi.org/10.1212/wnl.47.4_suppl_2.86s
Abstract
Two double-blinded, placebo-controlled clinical trials of riluzole have now been carried out in more than 1,100 patients with ALS. The results of both studies show a modest benefit in prolonging survival that is statistically significant. These results led to the availability of this drug by the Food and Drug Administration for use in the United States beginning in early 1996. This is the first drug that has been available for ALS. It begins a new era in both basic and clinical research in an attempt to find a cure for this disease. NEUROLOGY 1996;47(Suppl 2): S86-S92Keywords
This publication has 7 references indexed in Scilit:
- Pandora and the problem of evilThe Lancet, 1996
- The subunits of activator 1 (replication factor C) carry out multiple functions essential for proliferating-cell nuclear antigen-dependent DNA synthesis.Proceedings of the National Academy of Sciences, 1993
- NeurosarcoidosisNeurology, 1993
- Halothane–Morphine Compared with High-Dose Sufentanil for Anesthesia and Postoperative Analgesia in Neonatal Cardiac SurgeryNew England Journal of Medicine, 1992
- Distribution of Seizure Types in an Epileptic PopulationEpilepsia, 1988
- A tribute to Lewis P. RowlandNeurology, 1987
- Cardiovascular regulation and lesions of the central nervous systemAnnals of Neurology, 1985